0001209191-20-006279.txt : 20200204 0001209191-20-006279.hdr.sgml : 20200204 20200204161016 ACCESSION NUMBER: 0001209191-20-006279 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200131 FILED AS OF DATE: 20200204 DATE AS OF CHANGE: 20200204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arbuckle Stuart A CENTRAL INDEX KEY: 0001557290 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 20573783 MAIL ADDRESS: STREET 1: VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-01-31 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001557290 Arbuckle Stuart A C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, Chief Commercial Officer Common Stock 2020-01-31 4 M 0 4692 187.53 A 37932 D Common Stock 2020-01-31 4 S 0 4692 238.65 D 33240 D Common Stock 2020-02-03 4 M 0 2156 91.05 D 35396 D Common Stock 2020-02-03 4 M 0 1554 86.52 D 36950 D Common Stock 2020-02-03 4 S 0 440 228.90 D 36510 D Common Stock 2020-02-03 4 S 0 530 229.99 D 35980 D Common Stock 2020-02-03 4 S 0 1300 231.16 D 34680 D Common Stock 2020-02-03 4 S 0 900 231.87 D 33780 D Common Stock 2020-02-03 4 S 0 540 232.71 D 33240 D Common Stock 140 I 401(k) Stock Option (Right to Buy) 187.53 2020-01-31 4 M 0 4692 0.00 D 2029-02-05 Common Stock 4692 20334 D Stock Option (Right to Buy) 91.05 2020-02-03 4 M 0 2156 0.00 D 2026-02-01 Common Stock 2156 0 D Stock Option (Right to Buy) 86.52 2020-02-03 4 M 0 1554 0.00 D 2027-02-02 Common Stock 1554 6213 D Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $228.90 (range $228.37 to $229.11). Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $229.99 (range $229.48 to $230.46). Open market sales reported on this line occurred at a weighted average price of $231.16 (range $230.48 to $231.47). Open market sales reported on this line occurred at a weighted average price of $231.87 (range $231.50 to $232.44). Open market sales reported on this line occurred at a weighted average price of $232.71 (range $232.50 to $232.94). The option vests in 16 quarterly installments from 02/06/2019. Fully vested. The option vests in 16 quarterly installments from 02/03/2017. /s/ Omar White, Attorney-in-Fact 2020-02-04